AskGene Presents Encouraging Clinical Results on ASKB589 at ASCO-GI 2023
Camarillo, California, January 24, 2023 - AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Read More
AskGene Announces Completion of First Human Dosing of ASKG315, The First IL-15 Prodrug in Clinical Development
Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the first patient completed their first dose (Cycle 1, Day 1) Read More
AskGene Announces Clearance of IND Application by US FDA for ASKG915, A First-in-Class Anti-PD-1-IL-15 Prodrug Fusion Molecule for the Treatment of Patients with Solid Tumors
Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the United States Food and Drug Administration (FDA) has cleared its Read More
AskGene Announces Submission of IND to FDA for ASKG915
Camarillo, California, November 21st, 2022 - AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to Read More
AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022
Camarillo, California, November 15th, 2022 - AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Read More
AskGene Announces Appointment of Chief Medical Officer and VP of Preclinical & Clinical Pharmacology
Camarillo, California, August 19, 2022 – AskGene Pharma Inc. (AskGene) today announced the appointment of Barbara Hickingbottom, J.D., M.D. as Chief Medical Officer and Matt Read More
AskGene Pharma Announces First Development Milestone in License Agreement with AffaMed for the Development of ASKG712 in Retinal Disease
Camarillo, California, June 20, 2022 – AskGene Pharma Inc., an innovative clinical-stage biotech company, announces that its partner AffaMed has dosed the first patient in Read More
ASKB589 Achieved Partial Response in Phase I/II Clinical Trial
News, 2022-04-29 AskGene is pleased to announce that its lead program ASKB589 has recently achieved single agent efficacy in its on-going Phase I/II clinical trial. Read More
AM712 (ASKG712) IND Filing in USA
AffaMed Therapeutics (“AffaMed”), in collaboration with Askgene, announces that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application Read More
